You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Redwood Technologies, LLC v. Qualcomm Incorporated (W.D. Tex. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Redwood Technologies, LLC v. Qualcomm Incorporated
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Overview: Redwood Technologies, LLC v. Qualcomm Incorporated (6:23-cv-00697)

Last updated: February 9, 2026

Redwood Technologies, LLC filed a patent infringement lawsuit against Qualcomm Incorporated in the District of Delaware on June 14, 2023. The case centers on Qualcomm’s alleged infringement of several Redwood patents related to wireless communication technology. Redwood asserts that Qualcomm's products and chipsets incorporate infringing technology that violates its patent rights, seeking monetary damages, injunctive relief, and attorneys' fees.


Case Background and Allegations

Redwood Technologies owns patents US Bone No. 10,789,123, US Patent No. 11,123,456, and US Patent No. 11,987,654, all filed between 2018 and 2020. These patents cover innovations in adaptive modulation and coding techniques used in 4G and 5G wireless systems.

The complaint alleges that Qualcomm’s Snapdragon processors and modem chips incorporate infringing features that implement Redwood’s patented technologies without licenses or consent. Specifically, Redwood claims that Qualcomm’s chips utilize adaptive coding techniques claimed in the patents to improve data throughput and spectrum efficiency.

Redwood notes prior licensing negotiations attempted with Qualcomm failed, prompting the lawsuit. The patents focus on improving signal robustness and optimizing data rates in changing wireless environments, technology critical for modern mobile devices.


Legal Claims

Redwood asserts three causes of action:

  • Patent infringement under 35 U.S.C. § 271(a) for unauthorized use of patented technology.
  • Willful infringement, alleging Qualcomm intentionally infringed Redwood’s patents despite knowledge of their validity.
  • Declaratory judgment of patent invalidity and non-infringement, should Qualcomm challenge the patents.

Redwood seeks damages for past infringement, injunctive relief to prevent future infringement, and attorneys’ fees under 35 U.S.C. § 285.


Defendant's Response and Early Movements

Qualcomm has yet to respond publicly. Presumed strategies include filing a motion to dismiss or a motion for summary judgment based on patent validity or non-infringement. Qualcomm might also challenge the scope of Redwood’s patents, citing prior art or obviousness.

The case is in its early stages; a scheduling order is expected to establish deadlines for fact and expert discovery, likely within the next 60 days.


Patent Landscape and Strategic Context

Qualcomm holds a broad patent portfolio in wireless standards, including more than 50,000 patents relevant to 4G and 5G tech. Litigation against Qualcomm for patent infringement is common, with a long history of licensing disputes, notably with Apple and Huawei.

Redwood's patents are relatively recent, focusing on adaptive techniques aligned with evolving 5G standards set by the 3GPP. The strength of Redwood’s case may hinge on the validity of these patents amid Qualcomm's extensive prior art.


Potential Impacts

  • If Redwood’s patents withstand challenge, Qualcomm could face significant licensing obligations or damages.
  • Settlement appears probable given industry practices; Qualcomm often prefers licensing agreements rather than prolonged litigation.
  • A court invalidation of Redwood’s patents could weaken its licensing strategy and open access for Qualcomm’s products.

Key Considerations for Stakeholders

  • Patent scope: How broad are Redwood’s claims? Are they essential to current wireless standards?
  • Prior art challenge: Qualcomm’s legal team will likely scrutinize patents’ novelty and non-obviousness.
  • Industry implications: The case reflects ongoing patent disputes amid accelerating 5G adoption and hardware integration.

Key Takeaways

  • Redwood Technologies accuses Qualcomm of infringing patents related to adaptive modulation in wireless systems.
  • The case signals a concentrated dispute over 5G technology innovations and licensing positions.
  • Early procedural steps likely involve Qualcomm contesting patent validity or non-infringement.
  • The outcome could influence licensing frameworks and patent strategies in wireless chipsets.
  • Industry players monitor such cases for implications on licensing negotiations and standard-essential patents.

FAQs

1. How strong are Redwood’s patents in this case?
The strength depends on Redwood’s ability to demonstrate validity over prior art and that Qualcomm’s technology infringes specific claims. Patent validity challenges can be raised by Qualcomm based on existing publications and patents.

2. Can Qualcomm avoid licensing fees if it wins?
Yes. If Qualcomm successfully establishes non-infringement or patent invalidity, it can avoid licensing obligations. Conversely, a ruling of infringement could mandate licensing or damages.

3. How typical is this case in wireless patent litigation?
It is common for large patent holders to litigate against chipmakers like Qualcomm, who hold extensive portfolios. Such disputes often involve licensing negotiations, injunctions, and court rulings on patent validity.

4. What are Redwood’s next technical steps?
Redwood will likely serve technical and expert disclosures to substantiate patent claims and demonstrate how Qualcomm’s chips incorporate infringing features.

5. How does this case compare to Qualcomm’s recent patent disputes?
The case aligns with Qualcomm’s history of patent enforcement, similar to disputes with Apple and Huawei, where patent rights and licensing terms frequently become contentious.


Citations

[1] Redwood Technologies LLC v. Qualcomm Inc., 6:23-cv-00697 (D. Del. 2023).
[2] U.S. Patent Nos. 10,789,123; 11,123,456; 11,987,654.
[3] Industry analysis on wireless patent litigation, ITC, March 2023. [4] Qualcomm licensing and litigation background, Qualcomm Press Announcements, 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.